PostScript

MATTERS ARISING

Is IV infliximab better than IV methylprednisolone for the treatment of patients with RA when methotrexate fails?

A recent paper described a randomised comparative study of intravenous (IV) pulse methylprednisolone versus infliximab treatment in patients for whom methotrexate treatment had failed.¹ The conclusions that infliximab treatment offered substantial benefits over IV methylprednisolone may be correct, but the design of the trial has resulted in a biased assessment in favour of IV infliximab treatment. In addition, the failure of the IV methylprednisolone treatment to alter significantly a number of clinical and laboratory measures, including serum C reactive protein levels, is at odds with published reports.²⁻⁷

A comparison between the patient group in that study¹ and our previous papers on the use of IV methylprednisolone treatment²⁻⁶ suggests that the patients in each study had similar disease duration, seropositivity, and clinical and laboratory measures of disease activity. Two main differences between the two patient groups are the background corticosteroid use (none in our study and most patients in the study by Durez *et al*) and the use of methotrexate. It has been our anecdotal experience that patients receiving long term oral corticosteroids do not respond as well, or for as long, to IV methylprednisolone as do patients who are not receiving oral corticosteroids and may require more frequent administrations of IV methylprednisolone for the same effect. However, I am not aware of any published data to support this. Whether this might explain the lack of response to IV methylprednisolone in the study by Durez *et al* is unclear.

In addition, the comparison between a single dose of IV methylprednisolone and three infliximab infusions, while reflecting the authors' usual clinical practice, is certainly a comparison biased in favour of the infliximab treated patient group. It should be remembered that there are no published data to validate the requirement for infliximab infusions at 0, 2, and 6 weeks. Some evidence suggests that a more sustained response to daily infusions of 1000 mg methylprednisolone succinate for 3 days rather than a single IV infusion is preferable, and our own studies showed a mean duration of response of only 5.1 weeks, suggesting that repeated infusions with IV methylprednisolone might have resulted in more benefit from this treatment. It might have been better for the authors to compare either consecutive daily infusions for 3 days or monthly infusions of IV methylprednisolone, especially as the main outcome measures were at week 14 after treatment.

M D Smith

Rheumatology Unit, Repatriation General Hospital, Adelaide, South Australia

Rapid response

If you have a burning desire to respond to a paper published in the *Annals of the Rheumatic Diseases*, why not make use of our "rapid response" option?

Log on to our website (www.annrheumdis.com), find the paper that interests you, and send your response via email by clicking on the "eLetters" option in the box at the top right hand corner.

Providing it isn't libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on "read eLetters" on our homepage.

The editor will decide as before whether also to publish it in a future paper issue.

Correspondence to: Dr M D Smith; malcolm.smith@rgh.sa.gov.au

References

- 1 Durez P, Toukap AN, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, *et al*. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. *Ann Rheum Dis* 2004;63:1069-74.
- 2 Smith MD, Bertouch JV, Smith AM, Weatherall M, Ahern MJ, Brooks PM, *et al*. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. I. Clinical effects. *J Rheumatol* 1988;15:229-32.
- 3 Smith MD, Ahern MJ, Brooks PM, Roberts-Thomson PJ. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis. II. Effects on immune and inflammatory indices in peripheral blood. *J Rheumatol* 1988;15:233-7.
- 4 Williams JA, Baylis EM, Shipley ME. A double blind placebo controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. *Lancet* 1982;2:237-40.
- 5 Liebling MR. Pulse methylprednisolone therapy in active rheumatoid arthritis. *Internal Medicine for the Specialist* 1983;4:8.
- 6 Youssef PP, Cormack J, Evill CA, Peter DT, Roberts-Thomson PJ, Ahern MJ, Smith MD. Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis and the effects of methylprednisolone. *Arthritis Rheum* 1996;39:216-25.
- 7 Barry M. The use of high-dose pulse methylprednisolone in rheumatoid arthritis. *Arch Intern Med* 1985;145:1483-4.

Authors' reply

We thank Dr Smith for his comments on our study,¹ which were largely addressed by Buttgerit *et al*.² As already answered, the lack of significant response to intravenous methylprednisolone in our group of patients with rheumatoid arthritis (RA) is probably related to their disease severity, reflected by their previous treatments.

As an alternative hypothesis, suggested by Dr Smith, we can also speculate that our patients belong to a corticosteroid resistant RA subset. The mechanisms of resistance to steroids are unknown in RA but have recently been explored in patients with asthma.³

P Durez, T A Nzeusseu, B R Lauwerys, D H Manicourt, J-P Devogelaer, F A Houssiau
Rheumatology Department, Cliniques Universitaires Saint-Luc (Université catholique de Louvain), Belgium

P Verschueren, R Westhovens
UZ Gasthuisberg (Katholieke Universiteit Leuven), Belgium

Correspondence to: Dr F A Houssiau, Rheumatology Department, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Avenue Hippocrate 10, B-1200 Brussels, Belgium; housiau@ruma.ucl.ac.be

References

- 1 Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, *et al*. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. *Ann Rheum Dis* 2004;63:1069-74.
- 2 Buttgerit F, Burmester G, Bijlsma JW. Which dose regimen for glucocorticoid pulse therapy in patients with severe refractory RA? *Ann Rheum Dis* 2005;64:171-2.
- 3 Matthews JG, Ito K, Bames PJ, Adcock IM. Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. *J Allergy Clin Immunol* 2004;113:1100-8.

Antimicrobial treatment for Chlamydia induced reactive arthritis

We read with interest the article entitled "Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study".¹ The trial of Kvien *et al* suggests that weekly administration of azithromycin for 3 months is not efficacious in ameliorating the symptoms of reactive arthritis (ReA). Although this point seems clear, the authors then make a leap of faith and suggest that "this study does not support the prolonged use of antibiotics for the alleviation of ReA". There are several problems with this generalisation.

As Kvien *et al* correctly point out, polymerase chain reaction technology has documented the presence of *Chlamydia* and other causative organisms in the synovial tissue of patients with ReA.² This same technology has convincingly shown both in vitro and in vivo evidence of persistent metabolically active *Chlamydia*.³ The data on post-dysentery organisms have repeatedly demonstrated bacterial fragments,³ but viability has only been suggested in the case of *Yersinia*.⁴ This makes a strong argument for the use of antimicrobial agents in post-chlamydial ReA, yet both patients with post-venereal and post-dysentery ReA were included in this trial.

Previous therapeutic trials also suggest that post-chlamydial ReA is more susceptible to antimicrobial treatment than the post-dysentery form. A 1991 trial suggested that lymecycline was an effective treatment for post-chlamydial ReA, but not for the post-dysentery form.⁵ A subgroup analysis of post-chlamydial patients in another trial assessing

ciprofloxacin showed a trend towards improvement.⁶ There were not enough post-chlamydial patients in the trial of Kvien *et al* for a meaningful analysis to be made.

We also question the treatment itself in their trial. A one-time dose of 1000 mg of azithromycin is approved for an acute *Chlamydia* infection; however, the proper dose for persistent infection has not been established. To our knowledge, 1000 mg weekly has never even been studied in vitro as a dose to treat persistent *Chlamydia*. In addition, persistent *Chlamydia* infections intermittently shed infectious elementary bodies, potentially evading weekly pulse antimicrobial treatment. It has also been demonstrated that the chronic treatment of *Chlamydia trachomatis* with azithromycin in vitro caused the *Chlamydia* temporarily to arrest in a persistent viable state.⁷ Lastly, it has not been established if 3 months of a single antimicrobial agent is successful at treating an obligate intracellular organism that exists in the form of a reticulate body. Other obligate intracellular organisms, such as *Mycobacterium tuberculosis*, require 9 months of combination antimicrobial treatment to ensure therapeutic response.

Kvien *et al* implied that their trial, along with previous trials, indicates a lack of efficacy of antibiotics in ReA. The antibiotics studied previously included tetracyclines, ciprofloxacin, and now azithromycin.^{1,5,6} *Chlamydia* has demonstrated in vitro resistance to all of these antibiotics upon chronic administration.^{7,8} Further, ciprofloxacin has been shown to cause tendon based inflammation by potentiating interleukin 1 β stimulated metalloproteinase-3 output in tendons.⁹ Is this then the proper antibiotic to choose in the treatment of an enthesophyte based inflammatory arthritis?

We have recently completed a trial assessing a 9 month course of a combination of doxycycline and rifampin versus doxycycline monotherapy.¹⁰ The results showed a rather dramatic response in the patients who received the combination. The chlamydial resistance that has been documented in vitro, was overcome when a combination of antibiotics were used.⁷ Ours was the first trial to assess a combination of antibiotics in this setting.

Do antibiotics work in ReA, specifically *Chlamydia* induced ReA? In our opinion, this question has not been answered. We believe studies of large groups of patients, with the appropriate antibiotics, in the right dose, used for the proper length of time, need to be conducted before this question can be answered.

J D Carter, J Valeriano, F B Vasey
University of South Florida, Division of Rheumatology,
12901 Bruce B Downs Blvd, MDC 81 Tampa,
FL 33612, USA

Correspondence to: Dr J D Carter;
jocarter@hsc.usf.edu

References

- 1 Kvien TK, Gaston JSH, Bardin T, Butrimiene I, Dijkman BAC, Leirisalo-Repo M, *et al*. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. *Ann Rheum Dis* 2004;**63**:1113–19.
- 2 Gerard HC, Branigan PJ, Schumacher HR Jr, Hudson AP. Synovial chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome

are viable but show aberrant gene expression. *J Rheumatol* 1998;**25**:734–42.

- 3 Granfors K, Jalkanen S, Lindberg AA, Maki-Ikola O, von Essen R, Lahesmaa-Rantala R, *et al*. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. *Lancet* 1990;**335**:685–8.
- 4 Gaston JS, Cox C, Granfors K. Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. *Arthritis Rheum* 1999;**42**:2239–42.
- 5 Laihio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. *Arthritis Rheum* 1991;**34**:6–14.
- 6 Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, *et al*. No benefit of long-term ciprofloxacin in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. *Arthritis Rheum* 1999;**42**:1386–96.
- 7 Dreses-Werringloer U, Padubrin I, Zeidler H, Kohler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. *Antimicrob Agents Chemother* 2001;**45**:3001–8.
- 8 Dreses-Werringloer U, Padubrin I, Jurgens-Saathoff B, Hudson AP, Zeidler H, Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. *Antimicrob Agents Chemother* 2000;**44**:3288–97.
- 9 Corps AN, Harrall RL, Curry VA, Fenwick SA, Hazleman BL, Riley GP. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1 β in human tendon-derived cells. A potential mechanism for fluoroquinolone-induced tendinopathy. *Arthritis Rheum* 2002;**46**:3034–40.
- 10 Carter JD, Valeriano J, Vasey FB. Doxycycline vs. doxycycline and rifampin in undifferentiated spondyloarthritis – with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison. *J Rheumatol* 2004;**31**:1973–80.

Authors' reply

We thank Carter *et al*¹ for their valuable comments on our paper which reported the results of 3 months' treatment of reactive arthritis (ReA) with azithromycin.² The data from our study definitely did not support prolonged use of antibiotics for the alleviation of ReA, because no trend was found in favour of long term treatment. However, we do not disagree that the data from the study by Carter *et al*,¹ and from other authors,³ may support long term treatment with antibiotics in patients with ReA induced by *Chlamydia trachomatis*.

Such positive findings as have been reported seem to be restricted to this microbiological agent. We note that the study by Carter *et al*¹ was performed in patients with chronic undifferentiated spondyloarthritis with confirmed *Chlamydia* infection, but 9 of 30 patients had either a possible or probable preceding symptomatic *Chlamydia* infection.

We also agree that various arguments can be employed in the selection of the optimal antimicrobial agent in ReA. We chose azithromycin in our study because of its acceptable tolerability profile combined with a broad antimicrobial spectrum, as our study was designed to focus on all patients in whom ReA was a likely diagnosis—not just patients with *Chlamydia* induced ReA. Carter *et al* compared doxycycline 100 mg twice a day with doxycycline 100 mg twice a day + rifampicin 600 mg a day.¹ The latter drug is most widely used for the treatment of tuberculosis. The safety of this combination

should be clarified before recommendations are given for its wider use in ReA or undifferentiated spondyloarthritis.

We would also welcome an adequately powered trial confined to patients with *Chlamydia* induced arthritis, to clarify the efficacy or otherwise of long term treatment with antibiotics in this condition. However, in our opinion, such a trial will be difficult to perform, because of the logistic problems of recruiting large numbers of bacteriologically proven cases early in the course of their disease. For the present, therefore, clinicians must base their treatment on currently available data.

J S H Gaston

Department of Rheumatology, Addenbrooke's
Hospital, Box 157, Level 5, Hills Road, Cambridge
CB2 2QQ, UK

T K Kvien

Department of Rheumatology, Diakonhjemmet
Hospital, Oslo, Norway

Correspondence to: Professor J S H Gaston;
jshg2@medschl.cam.ac.uk

References

- 1 Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthritis, with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. *J Rheumatol* 2004;**31**:1973–80.
- 2 Kvien TK, Gaston JS, Bardin T, Butrimiene I, Dijkman BA, Leirisalo-Repo M, *et al*. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. *Ann Rheum Dis* 2004;**63**:1113–19.
- 3 Laihio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. *Arthritis Rheum* 1991;**34**:6–14.

Is Behçet's syndrome associated with infection?

I read with interest that the pustular skin lesions in Behçet's syndrome (BS) had been thought aseptic, were found to be not sterile, and that the microbiology of these lesions is different from ordinary acne.¹ I would like to report my observation of a patient with refractory pustulosis of Behçet's disease, who fulfilled the international study group criteria, was HLA-Bw51 positive, and had a family history of BS. The patient's skin rash disappeared after a 6 week course of cotrimoxazole (sulfamethoxazole-trimetoprim).

The patient, a 31 year old man had had recurrent oral and genital ulcers since childhood. Inflammatory joint disease developed 4 years ago, affecting shoulders, ankles, and knees, relapsing every 2–3 months. Recurrent knee effusions caused serious knee dysfunction. Skin pustulosis, which was episodic at onset, became persistent and massive during the past 4 years, affecting the body, back, and limbs (fig 1A). A skin vesicle was observed 24–48 hours after taking blood for analysis from the knee at the point of needle entry. Polyarthritis and skin pustulosis became refractory to local, systemic, and intra-articular corticosteroids and colchicine. The pustular lesions thought to be sterile in BS were not cultured. Salazopyrin, methotrexate given orally and parenterally at maximal dose of 25 mg/week, and azathioprine failed to control the knee effusions,

Figure 1 Pustulosis of Behçet's disease localised in the right suprascapular area: (A) before co-trimoxazole treatment; (B) on the 10th day of co-trimoxazole treatment (960 mg twice a day).

shoulder and ankle arthritis, skin rash, and oral ulcers. Invasive knee procedures were planned.

At this point the failed second line treatment was stopped, and we made the decision to start co-trimoxazole treatment. The rationale for this was the anti-inflammatory properties of the drug reported previously² and its effectiveness for some patients with Wegener's granulomatosis³ associated with severe neutrophilic activation,⁴ which is also seen in skin lesions of patients with BS.⁵

BS was reported to be associated with a higher incidence of *Streptococcus* mediated tonsillitis, and its adjuvant action to autoimmune disease cannot be excluded.⁶ Circulating immune complexes are thought to precipitate a neutrophilic vascular reaction, resulting in mucocutaneous lesions.^{7,8} A decrease in serum IgG and IgM was noted during co-trimoxazole treatment.²

Co-trimoxazole treatment was started with a daily dose of 50 mg/kg given in four divided doses (960 mg×4/day) for the first 3 days. Then the dose was reduced to 960 mg×3/day given for 1 week, followed by two double strength tablets a day until 6 weeks of treatment. The pustular rash gradually disappeared (figs 1A and B). After 6 weeks of the co-trimoxazole treatment the drug was stopped and weekly methotrexate injections were restarted at the previous dose. Knee effusion has relapsed only once during 1 year of follow up.

Evidence, that infection is the most probable environmental trigger of inflammatory joint disease is controversial, but interest in the topic is growing. The relationship between infection and collagen disease may be more subtle and complex than one of simply responding to Koch's postulates.⁹ Multiple infectious triggers which attack at an unknown rate, the delayed interval between infection and disease onset, and a role for primary, secondary, and persistent infection in the perpetuation of collagen

disease are the substance of the microbiology of rheumatic diseases. Bacteria are not only a source of exogenous antigens, which potentially cross react with those of the host, but can also exert adjuvant effects and release self antigens. Lipopolysaccharides, peptidoglycans, and bacterial DNA activate the innate immune system through specialised pattern recognition receptors of the Toll-like receptor family.¹⁰ Such microbial determinants are referred to as "pathogen associated molecular patterns". These patterns, together with the self antigens, activate the production of polyreactive antibodies, cytokine, and chemokines. Infected pustules of Behçet's disease might cause severe activation of the autoimmune response. Co-trimoxazole may be a promising treatment for controlling the microbial inductors and autoimmune reactions.

A P Rozin

B Shine Department of Rheumatology, Rambam Medical Centre and B Rappaport Faculty of Medicine, Israel-Technion Institute of Technology, Haifa, Israel

Correspondence to: Dr A Rozin, Department of Rheumatology, Rambam Medical Center, PO Box 9602, Haifa 31096, Israel; a_rozin@rambam.health.gov.il

References

- 1 Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, et al. The pustular skin lesions in Behçet's syndrome are not sterile. *Ann Rheum Dis* 2004;**63**:1450–2.
- 2 Rozin AP, Schapira D, Bergman R. Alopecia areata and relapsing polychondritis or mosaic autoimmunity. The first experience of co-trimoxazole treatment. *Ann Rheum Dis* 2003;**62**:778–80.
- 3 DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. *Mayo Clin Proc* 1985;**60**:27–32.
- 4 Brouwer E, Huitema MG, Mulder AHL, Heeringa P, van Goor H, Tervaert JWC, et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. *Kidney Int* 1994;**45**:1120–31.
- 5 Ackerman AB. Behçet's disease. In: Ackerman AB, Chongchitnant N, Sanchez J, et al. *Histologic diagnosis of inflammatory skin diseases*. In: *An algorithmic method based on pattern analysis*. 2nd ed. Baltimore: Williams & Wilkins, 1997:229–32.
- 6 Aoki K, Ohno S. Studies on the constitution and past history of patients with Behçet's disease. *Act Soc Ophthalmol Jpn* 1972;**76**:1608–12.
- 7 Williams BD, Lehner T. Immune complexes in Behçet's syndrome and recurrent oral ulcerations. *BMJ* 1977;**1**:1387–9.
- 8 Barton-Kee JE, Mowbray JF, Lehner T. Different cross-reacting circulating immune complexes in Behçet's disease and recurrent oral ulcers. *J Lab Clin Med* 1981;**97**:559–67.
- 9 Carty SM, Snowden N, Silman AJ. Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? *J Rheumatol* 2003;**30**:425–9.
- 10 Klinman D. Does activation of the innate immune system contribute to the development of rheumatoid arthritis? *Arthritis Rheum* 2003;**48**:590–3.

Authors' reply

We thank Dr Rozin for his interest in our article and sharing his experience about a patient with Behçet's syndrome (BS) who improved with co-trimoxazole. We also recently had a patient with BS who had severe pustulosis, arthritis, oral and genital ulcers and who similarly did well with antibiotics. *Staphylococcus aureus* grew from

both the dermal pustules and the pustular pathergy lesions.

Thus far there have been few formal studies of antibiotic use in BS. Çalgüneri *et al* reported that penicillin treatment was beneficial for the mucocutaneous lesions¹ and arthritis.² A similar beneficial effect was observed with minocycline, which reduced both the frequency of clinical symptoms and the production of inflammatory cytokines by peripheral blood mononuclear cells stimulated by streptococcal antigens.³

The issue of an infectious aetiology in BS has also long been discussed. Behçet himself proposed a viral aetiology.⁴ It has been suggested that viruses, such as herpes simplex virus⁵ and parvovirus,⁶ and bacteria including various streptococcal strains⁷ and staphylococci⁸ have a role.

In one study peripheral $\gamma\delta$ +CD8+T cells of patients with BS showed a significantly proliferative response to the *Streptococcus sanguis* strain KTH-1.⁷ In another, T cells from patients with BS produced interferon γ when stimulated with staphylococcal superantigens.⁸ Clinical evidence for the role played by an infectious agent in pathogenesis includes the presence of a higher incidence of chronic tonsillitis and dental caries in patients with BS,⁹ observation of exacerbations of BS symptoms after acute episodes of infection with *Streptococcus agalactiae* vaginitis,¹⁰ and gingival infections with methicillin resistant *Staphylococcus aureus*.¹¹

There are also reports from our group showing the association of papulopustular lesions with arthritis in BS, suggesting a reactive type of arthritis.^{12,13} Lehner and colleagues suggested that a common antigen such as a stress protein might be involved.¹⁴ A significant increase of IgA antibodies to mycobacterial 65 kDa heat shock protein (HSP) in the serum of patients with BS was shown. Owing to the significant homology between mammalian and microbial HSPs, it is suggested that recurrent exposure to HSP may cause bacterial HSP responsive T cells to stimulate autoreactive T cells by cross reactivity mechanisms. In turn, these T cells might produce Th1-like proinflammatory and/or inflammatory cytokines, leading to tissue injury.

Whatever the precise pathogenic pathways will turn out to be, it is clear that further controlled trials with antibiotics in BS are warranted.

G Hatemi, H Yazici

Division of Rheumatology, Department of Medicine, Cerrahpaşa Medical Faculty, University of Istanbul, Aksaray 34303, İstanbul, Turkey

Correspondence to: Dr H Yazici; hyazici@attglobal.net

References

- 1 Çalgüneri M, Erteli I, Kiraz S, Erman B, Çelik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. *Dermatology* 1996;**192**:125–8.
- 2 Çalgüneri M, Kiraz S, Erteli I, Benekli M, Karaaslan Y, Çelik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized clinical trial. *Arthritis Rheum* 1996;**39**:2062–5.
- 3 Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behçet's disease and clinical effects of minocycline on the disease symptoms. *Yonsei Med J* 1997;**38**:444–54.
- 4 Behçet H. Über Rezidivierende, aphthöse durch ein Virus verursachte Geschwüre am Mund, am Auge

- und an den Genitalien. *Dermatol. Wochenschr* 1937;105:1151–7.
- 5 **Eglin RP**, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. *Lancet* 1982;ii:1356–61.
 - 6 **Kiraz S**, Ertenli I, Benekli M, Çalgüneri M. Parvovirus B19 infection in Behçet's disease. *Clin Exp Rheumatol* 1996;14:71–3.
 - 7 **Mochizuki N**, Suzuki N, Takeno M, Nagafuchi H, Harada T, Kaneoka H. Fine antigen specificity of human gamma delta T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, *Streptococcus sanguis*. *Eur J Immunol* 1994;24:1536–43.
 - 8 **Hirohata S**, Hashimoto T. Abnormal T cell responses to bacterial superantigens in Behçet's disease. *Clin Exp Immunol* 1998;112:17–24.
 - 9 **Aoki K**, Ohno S. Studies on the constitution and past history of patients with Behçet's disease. *Acta Soc Ophthalmol Jpn* 1972;76:1608–12.
 - 10 **Lellouche N**, Belmonte N, Bourgoin P, Logeart D, Acar C, Cohen-Solal A, et al. Recurrent valvular relapse due to exacerbation of Behçet's disease by *Streptococcus agalactiae* infection. *Eur J Int Med* 2003;14:120–2.
 - 11 **Suga Y**, Tsuboi R, Kobayashi S, Ogawa H. A case of Behçet's disease aggravated by gingival infection with methicillin-resistant *Staphylococcus aureus*. *Br J Dermatol* 1995;133:319–21.
 - 12 **Diri E**, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: a controlled and masked study. *Ann Rheum Dis* 2001;60:1074–6.
 - 13 **Tunc R**, Keyman E, Melikoglu M, Fresko I, Yazici H. Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. *J Rheumatol* 2002;29:2393–6.
 - 14 **Lehner T**, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T. Association between the 65-kilodalton heat shock protein, *Streptococcus sanguis*, and the corresponding antibodies in Behçet's syndrome. *Infect Immun* 1991;59:1434–41.

Different threshold for prolactin response to hypoglycaemia in patients with rheumatoid arthritis?

In this issue of the *Annals* Eijsbouts and coworkers¹ show that the prolactin (PRL) response to hypoglycaemia is lower in patients with early untreated rheumatoid arthritis (RA) than in healthy controls. Furthermore, the unique design of their study allowed the authors to compare the PRL response before the test, after 2 weeks of treatment with a non-steroidal anti-inflammatory drug (NSAID) and, then again, after 6 months of conventional antirheumatic treatment with NSAIDs and disease modifying antirheumatic drugs (DMARDs). After 6 months they found that the PRL response to hypoglycaemia was significantly normalised, which correlated positively with the Disease Activity Score. The results of the study¹ suggest that disease activity and/or treatment with DMARDs significantly affects the central regulation of PRL secretion resulting from stimulation in patients with RA.

A possible involvement of PRL in the pathogenesis of inflammatory diseases has been intensively studied, including a hypothesis about dysregulated secretion of this pituitary hormone in patients with RA.² It has been shown that about one third of patients with RA are hyperprolactinaemic under basal conditions.² However, controversy remains about whether stimulated

secretion of PRL is up regulated or down regulated. Using the same stress stimulus as in the study of Eijsbouts *et al*,¹ we showed that the PRL response to hypoglycaemia was decreased in 38 patients with long term RA with moderate disease activity who were receiving treatment with NSAIDs or DMARDs.³ In line with others,^{4,5} we observed a PRL response to thyrotropin releasing hormone stimulation comparable to the response in healthy subjects in the same cohort of patients,³ suggesting a normal pituitary gland but altered central neuroendocrine regulatory mechanisms in patients with moderately active RA. The disease activity rather than the treatment itself seems have a more important effect on the PRL response to hypoglycaemia.

The PRL response to insulin-induced hypoglycaemia, unlike that of other pituitary hormones (for example, growth hormone), is not usually triggered in all healthy subjects, at least in a dose of 0.1 IU/kg of rapid acting insulin and may depend on an individual person's threshold for PRL release.⁶

In our most recent study we observed a lower PRL response to hypoglycaemia in glucocorticoid naive premenopausal patients with RA. When we analysed the data we found during hypoglycaemia that a double or higher increase of plasma PRL occurred only in 5/15 (33%) patients with RA but in 8/14 (57%) controls. PRL responses were irrespective of any clinical (disease activity, disease duration) or biochemical (tumour necrosis factor α , interleukin 6, C reactive protein, erythrocyte sedimentation rate) variables. The prevalence of PRL responders was not significantly different in patients with RA and controls, probably owing to the small sample size; however, the area under the response curve of PRL in patients with RA was significantly lower than in healthy controls.⁷ Nevertheless, we suggest that patients with RA may have a tendency towards a higher threshold for PRL release in response to hypoglycaemia, which deserves further investigation.

To test our proposal we would be interested in having the authors' view of their data in patients with RA and finding out whether the improvement in the PRL response in their study¹ was due to a quantitatively higher response in individual patients or rather a qualitative shift from being a PRL non-responding subject to a PRL responding subject.

R Imrich, M Vigas

Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia

J Rovensky

National Institute of Rheumatic Diseases, Piestany, Slovakia

Correspondence to: Dr R Imrich, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Vlárska 3, 833 06 Bratislava, Slovakia; richard.imrich@savba.sk

References

- 1 **Eijsbouts AM**, Van Den Hoogen FH, Laan RF, Sweep FC, Hermus AR, Van De Putte LB. Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. *Ann Rheum Dis* 2005; 64:433–7. doi:10.1136/ard.2002.001347 [Published Online First: 19 August 2004].
- 2 **Walker SE**, Jacobson JD. Roles of prolactin and gonadotropin-releasing hormone in rheumatic

diseases. *Rheum Dis Clin North Am* 2000;26:713–36.

- 3 **Rovensky J**, Bakosova J, Koska J, Ksinantova L, Jezova D, Vigas M. Somatotropic, lactotropic and adrenocortical responses to insulin-induced hypoglycemia in patients with rheumatoid arthritis. *Ann N Y Acad Sci* 2002;966:263–70.
- 4 **Gutierrez MA**, Garcia ME, Rodriguez JA, Mardonez G, Jacobelli S, Rivero S. Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. *J Rheumatol* 1999;26:277–81.
- 5 **Templ E**, Koeller M, Riedl M, Wagner O, Graninger W, Luger A. Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. *Br J Rheumatol* 1996;35:350–6.
- 6 **Cohen MP**, Gala RR. Failure of insulin hypoglycemia to produce rise in serum prolactin. *Am J Obstet Gynecol* 1975;121:1103–6.
- 7 **Rovensky J**, Imrich R, Malis F, Zlany M, Macho L, Koska J, et al. Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arthritis and ankylosing spondylitis. *J Rheumatol* 2004;31:2418–21.

Authors' reply

We thank the authors for their interest in our work and opportunity for discussion of this interesting but still puzzling subject. Published reports are contradictory, possibly because of different study subjects, different methods of stimulating prolactin (PRL) secretion, and large variation of PRL levels between individual subjects.

Indeed the study mentioned by the authors¹ showed that about one third of patients with rheumatoid arthritis (RA) were hyperprolactinaemic under basal conditions, and in our article we refer to other studies reporting hypersecretion of prolactin in RA. However, by now we have performed three studies in which we could not confirm this: (a) the study that is now being discussed, including a total of 50 patients with RA; (b) a former smaller study in patients before and after undergoing total hip replacement,² in which 10 patients with RA were compared with patients with osteoarthritis; and (c) a study in which we treated nine patients with RA with quinagolide, a dopamine agonist, which suppresses PRL secretion.³ None of these patients had raised PRL levels under basal conditions.

In our current study,² 17/20 (85%) healthy subjects had a double or higher increase in PRL levels in response to hypoglycaemia-induced stress, unlike the findings of the authors in their study, who found that only 57% of controls had a double or higher increase of PRL. They found PRL responses in patients with RA irrespective of disease activity, whereas in our study, as mentioned in the article, we found a negative correlation of PRL response and disease activity (DAS). We agree with the authors that it seems likely that disease activity is a more important factor in the changed PRL response than the treatment itself.

To answer the last question of the authors. In patients with RA we found that eight (40%) patients did not show a double or higher increase of PRL levels, and after treatment for 6 months only four did not show such a response, which could be consistent with the suggestion of Dr Imrich that more patients become PRL responding. However, 15/20 patients showed a marked increase in PRL levels after 6 months in response to hypoglycaemia-induced stress, and so we conclude that the improvement of the PRL response that we observed was

due to a general quantitatively higher response in most patients, and not a shift towards more patients being PRL responding.

A M M Eijbsbouts on behalf of the other authors

Department of Rheumatology, University Medical Centre, Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

Correspondence to: Dr A M M Eijbsbouts; a.eijbsbouts@maartenskliniek.nl

References

- 1 Walker SE, Jacobson JD. Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases. *Rheum Dis Clin North Am* 2000;26:713–36.
- 2 Eijbsbouts AM, Van Den Hoogen FH, Laan RF, Sweep FC, Hermus AR, Van De Putte LB. Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. *Ann Rheum Dis* 2005; 64:433–7, doi:10.1136/ard.002.001347 [Published Online First: 19 August 2004].
- 3 Eijbsbouts A, van den Hoogen F, Laan R, de Waal Malefijt M, Hermus A, Sweep C, et al. Similar response of adrenocorticotrophic hormone, cortisol and prolactin to surgery in rheumatoid arthritis and osteoarthritis. *Br J Rheumatol* 1998;37:1138–9.
- 4 Eijbsbouts A, van den Hoogen F, Laan R, Hermus A, Sweep C, van de Putte L. Treatment of rheumatoid arthritis with the dopamine-agonist quinagolide. *J Rheumatol* 1999;26:2284–5.

A costly therapeutic dilemma in tophaceous gout: is etanercept or rasburicase preferable?

Tausche *et al* described a case of severe tophaceous gouty arthritis, which was treated with etanercept.¹ They showed that anti-tumour necrosis factor α (TNF α) treatment can reduce the incidence of gouty attacks, which corresponds with the observation that TNF α is activated in patients with gouty arthritis.² Clearly, this is a costly symptomatic approach that is only in addition to the main treatment, which is lowering the serum uric acid (SUA) level in order to deplete urate depots and prevent gouty attacks and joint damage in the long term.

In the case presented, uricosuric treatment could only lower SUA levels from 0.58 mmol/l to 0.56 mmol/l despite high doses of 2–3 g probenecid a day. This is in contrast with our experience. In our population of 95% undersecretors (defined as uric acid excretion in urine <6.0 mmol/day during normal diet) monotherapy with probenecid 500 mg twice daily lowers SUA levels by 35% (mean (SD) 0.17 (0.05) mmol/l), whereas probenecid 500 mg twice daily in combination with allopurinol 200 mg daily lowers SUA levels by 48% (0.27 (0.08) mmol/l) in patients with an adequate renal function (endogenous creatinine clearance >50 ml/min).

In the case presented by Tausche *et al* we would like to suggest another option for treating patients with severe tophaceous gout—that is, treatment with rasburicase. This recombinant form of urate oxidase very effectively metabolises uric acid in allantoin, which dissolves readily and is excreted by urine. So far one patient has been treated by applying rasburicase and urate depots were

readily depleted (Moolenburgh JD *et al*, submitted paper).

In our opinion, for a case of severe tophaceous gout, when an expensive treatment is indicated, rasburicase should be considered as a potentially very effective treatment before using anti-TNF α .

M K Reinders, E N van Roon, J R B J Brouwers

Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, Henri Dunantweg 2, Leeuwarden, The Netherlands

T L Th A Jansen

Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands

Correspondence to: Mr M K Reinders; m.reinders@znb.nl

References

- 1 Tausche AK, Richter K, Grässler A, Hänslers S, Roch B, Schröder HE. Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor α as a new therapeutic option. *Ann Rheum Dis* 2004;63:1351–2.
- 2 McNearney T, Baethge BA, Cao S, Alam R, Lisse JR, Westlund KN. Excitatory amino acids, TNF- α , and chemokine levels in synovial fluids of patients with active arthropathies. *Clin Exp Immunol* 2004;137:621–7.

Authors' reply

Like Reinders *et al*, we have found that in the defined “normal” population of undersecretors, conventional treatment effectively lowers serum uric acid (SUA) levels to the norm.

In those critical cases of severe tophaceous gout, as presented by us, the multiple tophi in the tissue and joints contain around 50 g or more uric acid. Despite the escalation of antihyperuricaemic (uricosuric and uricostatic) drugs, the SUA levels cannot be lowered significantly because of uric acid mobilisation from these depots and secondary shift to the serum.

Therefore, measurement of SUA levels alone does not verify the efficiency of treatment.¹ In view of our own experience (unpublished data), we agree with Reinders *et al* that the recombinant urate oxidase rasburicase should be introduced into the treatment of severe tophaceous gout if conventional uric acid lowering treatment is not effective or contraindicated. These cases are extremely rare and occur in under 0.01% of the population of undersecretors.

There are two principles in the treatment of gout: firstly, uric acid lowering treatment with uricostatic and uricolytic agents and, secondly, anti-inflammatory treatment of gouty attacks. Both of these treatment regimens should follow a “step scheme”.¹

In the uric acid lowering treatment rasburicase might rank as the last step in treatment of patients with tophaceous gout. When gouty arthritis is refractory to treatment (with non-steroidal anti-inflammatory drugs, steroids, opioids) it is useful to introduce tumour necrosis factor α (TNF α) blockade, as we showed in the published case. Because two different principles of action can be followed there seems to be no need to answer the question of priority of one of these

treatments. Rasburicase should not be considered before TNF α blockade but, rather, the two should be combined if conventional treatment is not sufficient.

The main dilemma of both treatments in the first instance is not the high cost but the missing approval by the FDA in severe tophaceous gout.² Unfortunately, valid data are lacking, for instance, about the best way of application (dosage, application interval) owing to the absence of clinical studies. Shortly after infusion of rasburicase instant uric acid metabolism with abrupt decrease of SUA is observed. The resultant shift of uric acid from tissues to blood may cause a higher intensity of gouty attacks, and as we observed in one patient with urate nephropathy the worsening of renal function.³ We are very interested to learn of the article proposed by Moolenburgh *et al*.

A-K Tausche, H E Schröder

Section of Internal Medicine, Department of Rheumatology, University Clinic Carl Gustav Carus, Dresden University of Technology, Germany

Correspondence to: Dr A K Tausche; anne-kathrin.tausche@mailbox.tu-dresden.de

References

- 1 Thiele P, Schröder HE, Runge E. The treatment of essential hyperuricemia in graduated programs. *Z Arztl Fortbild* 1984;78:487–91.
- 2 Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. *J Clin Oncol* 2001;19:697–704.
- 3 Steele TH. Hyperuricemic nephropathies. *Nephron* 1999;81:45–9.

CORRECTION

doi: 10.1136/ard.2003.017087corr1

Prevalence and determinants of one month hand pain and hand related disability in the elderly (Rotterdam study) (Dahaghin S, Bierma-Zeinstra S M A, Reijman M, Pols H A P, Hazes J M W, Koes B W. *Ann Rheum Dis* 2005;64:99–104.)

We regret that table 5 of this paper mentioned on p 101 was omitted. This can now be found on the web at <http://www.annrheumdis.com/supplemental>

Corrections printed in the journal also appear on the *Annals* website <http://www.annrheumdis.com> and are linked to the original publication

FORTHCOMING EVENTS

Future events can be found on the website at <http://annrheumdis.com>